PMID- 20581680
OWN - NLM
STAT- MEDLINE
DCOM- 20101214
LR  - 20220316
IS  - 1473-6551 (Electronic)
IS  - 1350-7540 (Linking)
VI  - 23
IP  - 5
DP  - 2010 Oct
TI  - Acquired myasthenia gravis in childhood.
PG  - 536-40
LID - 10.1097/WCO.0b013e32833c32af [doi]
AB  - PURPOSE OF REVIEW: This review discusses recent studies on myasthenia gravis with 
      onset in childhood (juvenile myasthenia gravis) and neonatal myasthenia gravis. 
      RECENT FINDINGS: The occurrence of myasthenia gravis in childhood is strongly 
      influenced by genetic and environmental factors. Juvenile myasthenia gravis is 
      associated with antibodies to the acetylcholine receptor (AChR) in most patients. 
      Thymoma is rare, but often malignant in children. The frequency of juvenile 
      myasthenia gravis with antibodies to the muscle-specific kinase (MuSK) varies 
      markedly in different countries; some distinct features have been described. 
      Management of juvenile myasthenia gravis does not differ, on the whole, from that 
      of adult myasthenia gravis. Timing of thymectomy in young children is still 
      controversial. Maternal antifetal type AChR antibodies can cause persistent focal 
      weakness in the offspring, while neonatal myasthenia gravis associated with MuSK 
      antibodies is often a severe and protracted albeit transient disease. SUMMARY: 
      Juvenile myasthenia gravis, like its adult-onset counterpart, is a heterogeneous 
      disease. Clinical presentation is influenced by antibody status, ethnicity and 
      age of onset. Treatment is very effective, but guidelines and controlled trials 
      are needed.The risk for neonatal myasthenia gravis appears to be markedly 
      influenced by maternal antibody subclass and antigen specificity. Adequate 
      treatment in mothers can reduce both frequency and severity of neonatal disease.
FAU - Evoli, Amelia
AU  - Evoli A
AD  - Neuroscience Department, Catholic University, Roma, Italy. a.evoli@rm.unicatt.it
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Neurol
JT  - Current opinion in neurology
JID - 9319162
RN  - 0 (Autoantibodies)
RN  - 0 (Receptors, Cholinergic)
RN  - EC 2.7.10.1 (MUSK protein, human)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Age of Onset
MH  - Autoantibodies/immunology
MH  - Humans
MH  - Myasthenia Gravis/classification/epidemiology/*genetics/*physiopathology
MH  - Myasthenia Gravis, Neonatal/genetics/physiopathology
MH  - Receptor Protein-Tyrosine Kinases/immunology
MH  - Receptors, Cholinergic/immunology
EDAT- 2010/06/29 06:00
MHDA- 2010/12/16 06:00
CRDT- 2010/06/29 06:00
PHST- 2010/06/29 06:00 [entrez]
PHST- 2010/06/29 06:00 [pubmed]
PHST- 2010/12/16 06:00 [medline]
AID - 10.1097/WCO.0b013e32833c32af [doi]
PST - ppublish
SO  - Curr Opin Neurol. 2010 Oct;23(5):536-40. doi: 10.1097/WCO.0b013e32833c32af.